Education
About Us
Working with TipRanks
Follow Us
DENTSPLY SIRONA (XRAY)
:XRAY
XRAY Analyst Ratings
Moderate Buy
4 Buy
11 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
XRAY Stock 12 Month Forecast
Average Price Target
$19.92
▲(27.69% Upside)
| Highest Price Target$27.00 | Average Price Target$19.92 | Lowest Price Target$17.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Needham
Downgraded
03/13/25
Mizuho Securities
Reiterated
03/12/25
Jefferies
Reiterated
03/06/25
J.P. Morgan
Reiterated
03/01/25
Morgan Stanley
Reiterated
02/28/25
Robert W. Baird
Reiterated
02/28/25
Stifel Nicolaus
Reiterated
02/28/25
Barrington
Reiterated
02/28/25
Piper Sandler
Reiterated
02/28/25
Bank of America Securities
$20→$19
Hold
21.79%
Upside
Reiterated
02/27/25
Hold Rating for DENTSPLY SIRONA Amid Cost-Cutting and Market ChallengesWe lower to multiple to reflect softer organic growth in the near-term. Lowering FY25 revenue, but raising FY25 EPS estimates We are reducing our FY25 revenue estimate from $3,721MM to $3,601.0MM. We are raising our 2025 adj. EPS from $1.69 to $1.80. The reduction in our revenue estimates is primarily driven by lower organic growth across the Solutions segments. Our EPS estimates increase to reflect better operating leverage on cost savings from restructuring and Byte marketing/G&A spend exiting the model, more than offsetting lower revenue.
Leerink Partners
$21→$19
Hold
21.79%
Upside
Reiterated
02/27/25
Hold Rating Maintained for DENTSPLY SIRONA Amid Market Challenges and Strategic Uncertainty
Wells Fargo
$20→$19
Hold
21.79%
Upside
Reiterated
02/27/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alphatec Holdings (NASDAQ: ATEC), Verona Pharma (NASDAQ: VRNA) and DENTSPLY SIRONA (NASDAQ: XRAY)
William Blair
―
Buy
―
Reiterated
02/27/25
DENTSPLY SIRONA: Overcoming Challenges with Strategic Initiatives and Market Positioning for Long-Term Growth
Evercore ISI
$20
Hold
28.21%
Upside
Reiterated
02/27/25
Evercore ISI Keeps Their Hold Rating on DENTSPLY SIRONA (XRAY)
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Needham
Downgraded
03/13/25
Mizuho Securities
Reiterated
03/12/25
Jefferies
Reiterated
03/06/25
J.P. Morgan
Reiterated
03/01/25
Morgan Stanley
Reiterated
02/28/25
Robert W. Baird
Reiterated
02/28/25
Stifel Nicolaus
Reiterated
02/28/25
Barrington
Reiterated
02/28/25
Piper Sandler
Reiterated
02/28/25
Bank of America Securities
$20→$19
Hold
21.79%
Upside
Reiterated
02/27/25
Hold Rating for DENTSPLY SIRONA Amid Cost-Cutting and Market ChallengesWe lower to multiple to reflect softer organic growth in the near-term. Lowering FY25 revenue, but raising FY25 EPS estimates We are reducing our FY25 revenue estimate from $3,721MM to $3,601.0MM. We are raising our 2025 adj. EPS from $1.69 to $1.80. The reduction in our revenue estimates is primarily driven by lower organic growth across the Solutions segments. Our EPS estimates increase to reflect better operating leverage on cost savings from restructuring and Byte marketing/G&A spend exiting the model, more than offsetting lower revenue.
Leerink Partners
$21→$19
Hold
21.79%
Upside
Reiterated
02/27/25
Hold Rating Maintained for DENTSPLY SIRONA Amid Market Challenges and Strategic Uncertainty
Wells Fargo
$20→$19
Hold
21.79%
Upside
Reiterated
02/27/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alphatec Holdings (NASDAQ: ATEC), Verona Pharma (NASDAQ: VRNA) and DENTSPLY SIRONA (NASDAQ: XRAY)
William Blair
―
Buy
―
Reiterated
02/27/25
DENTSPLY SIRONA: Overcoming Challenges with Strategic Initiatives and Market Positioning for Long-Term Growth
Evercore ISI
$20
Hold
28.21%
Upside
Reiterated
02/27/25
Evercore ISI Keeps Their Hold Rating on DENTSPLY SIRONA (XRAY)
XRAY Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
1
1
1
1
1
Buy
15
11
5
7
6
Hold
10
10
14
19
19
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
26
22
20
27
26
Each month's total comprises the sum of three months' worth of ratings.
XRAY Financial Forecast
XRAY Stock Forecast FAQ
What is XRAY’s average 12-month price target, according to analysts?
Based on analyst ratings, DENTSPLY SIRONA’s 12-month average price target is $19.92.
What is XRAY’s upside potential, based on the analysts’ average price target?
DENTSPLY SIRONA has 27.69% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is XRAY a Buy, Sell or Hold?
DENTSPLY SIRONA has a consensus rating of Moderate Buy which is based on 4 buy ratings, 11 hold ratings and 0 sell ratings.
What is DENTSPLY SIRONA’s price target?
The average price target for DENTSPLY SIRONA is $19.92. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $27.00 ,the lowest forecast is $17.00. The average price target represents 27.69% Increase from the current price of $15.6.
The highest analyst price target is $27.00 ,the lowest forecast is $17.00. The average price target represents 27.69% Increase from the current price of $15.6.
What do analysts say about DENTSPLY SIRONA?
DENTSPLY SIRONA’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
How can I buy shares of XRAY?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.